123 related articles for article (PubMed ID: 34458991)
1. Hinge influences in murine IgG binding to Cryptococcus neoformans capsule.
Oliveira DSL; Paredes V; Caixeta AV; Henriques NM; Wear MP; Albuquerque P; Felipe MSS; Casadevall A; Nicola AM
Immunology; 2022 Jan; 165(1):110-121. PubMed ID: 34458991
[TBL] [Abstract][Full Text] [Related]
2. The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant Klebsiella pneumoniae.
Motley MP; Diago-Navarro E; Banerjee K; Inzerillo S; Fries BC
mBio; 2020 Sep; 11(5):. PubMed ID: 32900809
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
4. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD
J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499
[TBL] [Abstract][Full Text] [Related]
5. Antibody interactions with the capsule of Cryptococcus neoformans.
Feldmesser M; Rivera J; Kress Y; Kozel TR; Casadevall A
Infect Immun; 2000 Jun; 68(6):3642-50. PubMed ID: 10816523
[TBL] [Abstract][Full Text] [Related]
6. Variable Region Identical IgA and IgE to Cryptococcus neoformans Capsular Polysaccharide Manifest Specificity Differences.
Janda A; Eryilmaz E; Nakouzi A; Pohl MA; Bowen A; Casadevall A
J Biol Chem; 2015 May; 290(19):12090-100. PubMed ID: 25778397
[TBL] [Abstract][Full Text] [Related]
7. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice.
Yuan RR; Spira G; Oh J; Paizi M; Casadevall A; Scharff MD
Infect Immun; 1998 Mar; 66(3):1057-62. PubMed ID: 9488395
[TBL] [Abstract][Full Text] [Related]
8. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
9. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
10. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen.
Torres M; Fernández-Fuentes N; Fiser A; Casadevall A
J Biol Chem; 2007 May; 282(18):13917-27. PubMed ID: 17353196
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
13. Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.
Cleare W; Mukherjee S; Spitzer ED; Casadevall A
Clin Diagn Lab Immunol; 1994 Nov; 1(6):737-40. PubMed ID: 8556529
[TBL] [Abstract][Full Text] [Related]
14. Human T cell activation induced by a monoclonal mouse IgG3 anti-CD3 antibody (RIV9) requires binding of the Fc part of the antibody to the monocytic 72-kDa high-affinity Fc receptor (FcRI).
Ceuppens JL; Van Vaeck F
Cell Immunol; 1989 Jan; 118(1):136-46. PubMed ID: 2521302
[TBL] [Abstract][Full Text] [Related]
15. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
Mukherjee J; Nussbaum G; Scharff MD; Casadevall A
J Exp Med; 1995 Jan; 181(1):405-9. PubMed ID: 7807020
[TBL] [Abstract][Full Text] [Related]
16. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.
Zebedee SL; Koduri RK; Mukherjee J; Mukherjee S; Lee S; Sauer DF; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Jul; 38(7):1507-14. PubMed ID: 7979280
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
[TBL] [Abstract][Full Text] [Related]
18. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Casadevall A; Cleare W; Feldmesser M; Glatman-Freedman A; Goldman DL; Kozel TR; Lendvai N; Mukherjee J; Pirofski LA; Rivera J; Rosas AL; Scharff MD; Valadon P; Westin K; Zhong Z
Antimicrob Agents Chemother; 1998 Jun; 42(6):1437-46. PubMed ID: 9624491
[TBL] [Abstract][Full Text] [Related]
20. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
Nussbaum G; Cleare W; Casadevall A; Scharff MD; Valadon P
J Exp Med; 1997 Feb; 185(4):685-94. PubMed ID: 9034147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
